J Neurogastroenterol Motil  
Aloe Vera is Effective and Safe in Short-term Treatment of Irritable Bowel Syndrome: A Systematic Review and Meta-analysis
Seung Wook Hong1, Jaeyoung Chun1*, Sunmin Park2, Hyun Jung Lee1, Jong Pil Im1, Joo Sung Kim1
1Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, Korea., 2Department of Food & Nutrition, Hoseo University, Asan, Korea.
Correspondence to: Jaeyoung Chun, MD
Department of Internal Medicine and Liver Research Institute, Seoul National University
College of Medicine, 101 Daehak-ro, Jongno-gu, Seoul 03080, Korea
Tel: +82-2-740-8112, Fax: +82-2-743-6701, E-mail: j40479@snu.ac.kr
Received: April 23, 2018; Revised: June 5, 2018; Accepted: July 12, 2018; Published online: August 29, 2018.
© The Korean Society of Neurogastroenterology and Motility. All rights reserved.

cc This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
To evaluate the efficacy and safety of Aloe vera (AV) in patients with irritable bowel syndrome (IBS).
We searched the MEDLINE, EMBASE, and Cochrane databases for studies dated between 1st January 1960 and 30th December 2017. Eligible randomized controlled trials (RCTs) compared AV to placebo in patients with IBS. The primary outcome was standardized mean difference of the change in severity of IBS symptoms as measured by patient-rated scales. Secondary outcomes included response rate of IBS symptoms and adverse events. Heterogeneity among studies was assessed using Cochrane’s Q and I2 statistics.
Three RCTs with a total of 151 patients with IBS were included. The meta-analysis showed a significant difference for patients with AV compared to those with placebo regarding improvement in IBS symptom score (standardized mean difference, 0.41; 95% CI, 0.07-0.75; P = 0.020). Using intention-to-treat analysis, the AV patients showed significantly better response rates of IBS symptoms compared to placebo (pooled risk ratio, 1.69; 95% CI, 1.05-2.73; P = 0.030). No adverse events related with AV were found in included studies. There was no significant heterogeneity of effects across studies (P = 0.900; I2 = 0%).
AV is effective and safe for the treatment of patients with IBS compared to placebo.
Keywords: Aloe, Irritable bowel syndrome, Meta-analysis, Review

This Article



Aims and Scope